The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1483
December 7, 2015
View Complete Issue         Table of Contents 2019 
Ferric Citrate (Auryxia) for Hyperphosphatemia
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Ferric Citrate (Auryxia) for Hyperphosphatemia
December 7, 2015 (Issue: 1483)
The FDA has approved ferric citrate (Auryxia – Keryx), an oral phosphate binder, for treatment of hyperphosphatemia in patients with chronic kidney disease (CKD) on dialysis. It is the second iron-based phosphate binder to be approved in the...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Ferric Citrate (Auryxia) for Hyperphosphatemia
Article code: 1483d
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.